Article
DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the…
bioRxiv · 2023 · Ernie Yulyaningsih
Key facts
| Title | DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response |
|---|---|
| First author | Ernie Yulyaningsih |
| Journal | bioRxiv |
| Published | Oct 10, 2023 |
| DOI | 10.1101/2023.08.21.554203 |
| Devices mentioned | K800552, K853723, K860811, K862004, K874160, K874609, K912581, K915561, K915840, K920529, K920967, K923274 and 10 more |
| Product codes mentioned | EPT, GCJ, GCT, GEX, HET, HJO, HLI, HLQ, HQF, KKX, JJH, LXG and 2 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1